SHINEWAY PHARM2877.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 16, 2026, SHINEWAY PHARM (2877.HK) trades at a P/E of 6.64x, P/B of 0.65x, P/S of 2.02x, and a dividend yield of 25.92%.
Longitudinal percentile comparison: P/E sits at the 16th percentile over the trailing 10Y window (vs. 41st percentile over 3Y); P/B sits at the 5th percentile over the trailing 10Y window (vs. 2nd percentile over 3Y); P/S sits at the 65th percentile over the trailing 10Y window (vs. 83rd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 43rd percentile within its industry and the 28th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 25.92%, ranking at the 100th percentile over the trailing 20Y window.
Cross-checking P/E against P/B, the two percentiles sit within 10.1 points of each other — a consistent signal from both angles. The P/E percentile sits lower across the market than within its own industry — relatively cheaper next to the market as a whole. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. SHINEWAY PHARM operates in the Traditional Chinese Medicine Production sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 2877 · SEHK: 2877 · 2877
Want the full picture on whether SHINEWAY PHARM (2877.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 6.64 | ||||||
| P/B (MRQ) | 0.65 | ||||||
| P/S (TTM) | 2.02 | ||||||
| Dividend Yield | 25.92% | ||||||
| Buyback + Div Yield | 25.92% |